These treat conditions like hypertrophic cardiomyopathy, and intractable epilepsy. China’s National Healthcare Security ...

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.

Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following a year of strong gains, ...

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

The Max Foundation expands collaboration with Novartis to include access to innovative treatment for paroxysmal nocturnal hemoglobinuria: Seattle, Washington Monday, December 9, 2 ...

in patients with paroxysmal nocturnal hemoglobinuria (PNH). Results were shared during an oral session at the American ...

Pharmaceuticals announced updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its ...

A total of 13 rare-disease drugs have been added to the latest edition of China medical insurance drug catalog bringing the total amount of such medi ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial ...

New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...

Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...